US2001005729A1PendingUtilityA1

Rapidly absorbed liquid compositions

Priority: Jun 10, 1999Filed: Feb 5, 2001Published: Jun 28, 2001
Est. expiryJun 10, 2019(expired)· nominal 20-yr term from priority
A61P 29/02A61P 29/00A61P 11/02A61P 11/00A61K 9/10A61K 31/137A61K 31/19A61K 31/13
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method for providing enhanced absorption of a pharmaceutically acceptable amine into the blood of a human comprising providing a pharmacologically effective dosage of a pharmaceutically acceptable amine and an effective amount of a nonsteroidal anti-inflammatory acidic drug in a stable liquid form.  
     
     
         2 . The method of    claim 1    wherein the enhanced absorption is indicated by AUC 1 H (early drug exposure) that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.  
     
     
         3 . The method of    claim 1    wherein the enhanced absorption is indicated by AUC 2 H (early drug exposure) that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.  
     
     
         4 . The method of    claim 1    wherein the enhanced absorption is indicated by a CMAX (maximum or peak concentration) that is at least about 10% greater than the CMAX of the same amine from a single-ingredient liquid.  
     
     
         5 . The method of    claim 1    wherein the stable liquid form is a suspension.  
     
     
         6 . The method of    claim 1    wherein the amine is pseudoephedrine.  
     
     
         7 . The method of    claim 1    wherein the nonsteroidal anti-inflammatory drug is ibuprofen.  
     
     
         8 . the method of    claim 6    wherein the pseudoephedrine is provided in a range from about 15 mg to about 60 mg per dosage unit.  
     
     
         9 . The method of    claim 6    wherein the pseudoephedrine is provided in a range from about 15 mg to about 45 mg per dosage unit.  
     
     
         10 . The method of    claim 7    wherein the ibuprofen is provided in an amount of from about 40 mg to about 800 mg per dosage unit.  
     
     
         11 . The method of    claim 7    wherein the ibuprofen is provided in an amount of from about 40 mg to about 300 mg per dosage unit.  
     
     
         12 . The method of    claim 1    wherein the amine is pseudoephedrine at about 15 milligrams and the nonsteroidal anti-inflammatory is ibuprofen provided at a level at about 100 milligrams per 5 mL.  
     
     
         13 . The method of    claim 1    wherein the human is a child.  
     
     
         14 . A composition comprising a pharmacologically effective amount of a pharmaceutically acceptable amine and a pharmacologically effective amount of a nonsteroidal anti-inflammatory drug, said amine and nonsteroidal anti-inflammatory drug are provided in a stable liquid form.  
     
     
         15 . The composition of    claim 14    wherein the stable liquid form is a suspension.  
     
     
         16 . The composition of    claim 14    wherein the nonsteroidal anti-inflammatory drug is ibuprofen and the pharmaceutically acceptable amine is pseudoephedrine.  
     
     
         17 . The composition of    claim 16    wherein the ibuprofen is provided at dosage of about 100 milligrams and the pseudoephedrine is provided at a dosage of about 15 milligrams per 5 mL.

Join the waitlist — get patent alerts

Track US2001005729A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.